Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety

Reyad Dada, MD, Azhar Nawaz, Clinical Pharmacy Specialist, Ehab Mosaad Abdelghany, MD, Tarek Boubakra

Blood (2018) 132 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2018-99-111538

Published: 2018

Journal Articles

A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation

Mingzi Yang, MD, Meng Wu, MD, Reyizha Nuersulitan, MD, Yanfei Liu, MD, Liya A, MD, Lingyan Ping, MD PhD, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2018-99-112385

Published: 2018

Journal Articles

Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential R-CHOP/R- ICE Regimen Omitting Radiation

Neta Goldschmidt, MD, Ora B. Paltiel, MDM, MSc, Dina Ben Yehuda, Geffen Kleinstern, Alexander Gural, MD, Diana Libster, MD, David Lavie, MD, Moshe E. Gatt, MD

Blood (2015) 126 (23): 3954.

https://doi.org/10.1182/blood.V126.23.3954.3954

Published: 2015

Journal Articles

Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities

Norina Tanaka, MD PhD, Yoichi Imai, MD PhD, Aya Watanabe, MD, Kenjiro Mitsuhashi, MD PhD, Kentaro Yoshinaga, MDPhD, Masayuki Shiseki, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD, PhD

Blood (2015) 126 (23): 2713.

https://doi.org/10.1182/blood.V126.23.2713.2713

Published: 2015

Journal Articles

Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases

Sylvain Choquet, MD, Adrien Grenier, MD, Caroline Houillier, MD, Carole Soussain, MD PhD, Marie Pierre Moles, MD, Thomas Gastinne, MD, Nathalie Cassoux, MD, Helene merle Beral, MD, Damien roos Weil, MD, Veronique Leblond, MD PhD, Khe hoang Xuan, MD PhD

Blood (2015) 126 (23): 1524.

https://doi.org/10.1182/blood.V126.23.1524.1524

Published: 2015

Journal Articles

High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory Primary Central-Nervous System and Intra-Ocular Non Hodgkin Lymphoma, After First Line Treatment Containing High Doses of Methotrexate and Cytarabine. A Monocentric Retrospective Study From 2010 to 2012 On 17 Cases

Sylvain Choquet, MD, Damien roos Weil, MD, Khe Hoang Xuan, MD, Nathalie Cassoux, Helene Merle-Beral, Veronique Leblond

Blood (2012) 120 (21): 3664.

https://doi.org/10.1182/blood.V120.21.3664.3664

Published: 2012

Journal Articles

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Swaminathan Padmanabhan, MBBS, MD, Thomas C. Shea, MD, Julie M. Vose, MD, Craig B. Reeder, MD, Jesus G Berdeja, MD, Kevin T. McDonagh, MD, Andre Goy, MD, Kevin R Kelly, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, Howard Fingert, MD, Nathan Fowler, MD

Blood (2010) 116 (21): 2799.

https://doi.org/10.1182/blood.V116.21.2799.2799

Published: 2010

Journal Articles

How to Manage Refractory T-Cell Leukemia-Lymphomas in Children? A Question to Be Answered, Yet!

Antonella Sau, Daniela Onofrillo, Amelia Poli, Gaetano La Barba, Luca Lo Nigro

Blood (2009) 114 (22): 4777.

https://doi.org/10.1182/blood.V114.22.4777.4777

Published: 2009

Journal Articles

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Anna Vanazzi, MD, Alessandra Alietti, MD, Alberto Agazzi, MD, Mara Negri, Maria Teresa Lionetti, Aleksandra Babic, Davide Radice, Luca Nassi, MD, Simona Sammassimo, MD, Cristina Rabascio, Pierluigi Antoniotti, Lara Roveda, Bruno Lucchetti, Tiziana Suardi, Alessio Piredda, Liliana Calabrese, Giovanni Martinelli, MD, Daniele Laszlo, MD

Blood (2009) 114 (22): 3210.

https://doi.org/10.1182/blood.V114.22.3210.3210

Published: 2009

Journal Articles

Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma.

Yuksel Urun, MD, Huseyin Abali, Md, Berna Oksuzoglu, Md, Burcin Budakoglu, Md, Nuriye Yildirim, Md, Tunc Guler, Md, Gulsum Ozet, Md, Nurullah Zengin, Md

Blood (2007) 110 (11): 4438.

https://doi.org/10.1182/blood.V110.11.4438.4438

Published: 2007

Journal Articles

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Carol Portlock, David Straus, Ariela Noy, Owen O'Connor, Daniel A. Filippa, Julie Teruya-Feldstein, Alison Gencarelli, Jing Qin, Alyson Waxman, Joachim Yahalom, Craig H. Moskowitz

Blood (2004) 103 (10): 3684–3688.

https://doi.org/10.1182/blood-2003-11-3911

Published: 2004

NARROW

Outpatient Fractionated ICE Protocol in Relapsed/Refractory Lymphomas: Efficacy and Safety

A Retrospective Study of 108 Cases of Relapsed or Refractory Classical Hodgkin Lymphoma: Second Line Therapies and Autologous Hematopoietic Stem Cell Transplantation

Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential R-CHOP/R- ICE Regimen Omitting Radiation

Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities

Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases

High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory Primary Central-Nervous System and Intra-Ocular Non Hodgkin Lymphoma, After First Line Treatment Containing High Doses of Methotrexate and Cytarabine. A Monocentric Retrospective Study From 2010 to 2012 On 17 Cases

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

How to Manage Refractory T-Cell Leukemia-Lymphomas in Children? A Question to Be Answered, Yet!

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only